Marc Thibonnier, M.D., M.Sc.
- Dr. Thibonnier is the Founder and President of AptamiR Therapeutics, Inc. As a Physician-Scientist, he led a successful career in academic medicine in France and the USA up to the rank of tenured Professor of Medicine and Pharmacology at Case Western Reserve University School of Medicine, followed by several years in executive leadership positions at major Pharmaceutical Companies (Bayer Health Care, BMS, and GSK) and two Biotechnology Startup Companies, overseeing cardiovascular and metabolic drugs development from candidate selection to regulatory approval.
- Dr. Thibonnier earned a M.D. degree with High Honors from the Université Pierre et Marie Curie in Paris, France and a M.Sc. in Pharmacology from the University of California, San Francisco where he completed his fellowship in clinical pharmacology. He trained in Endocrinology, Nephrology and Clinical Pharmacology.
Philippe Camus, Ph.D.
- Philippe Camus is the Chairman of the Board of AptamiR. He is currently a Senior Adviser at Evercore Partners. He is the former Chairman of the Board at Alcatel–Lucent/Nokia and the former CEO of EADS and co-managing partner at Lagardère
- Philippe Camus graduated from the Ecole Normale Supérieure and the Institut d’Etudes Politiques de Paris
Jean-Pierre Lehner, M.D.
- Dr. Lehner is a Director on the AptamiR Board. He is the retired Chief Medical Officer of Sanofi, with previous positions at Roussel, Roussel-UCLAF, and Sanofi Winthrop. Currently, he is CEO of JPL Pharma Consulting and a Board Member of several biotech and R&D companies.
- Dr. Lehner earned an M.D. degree from the University of Paris School of Medicine with specialty training in cardiology.
Mr. Poussot has been an Advisor for AptamiR since 2012. He was formerly the Chairman, CEO, & President of Wyeth Pharmaceuticals, until their acquisition by Pfizer in 2009. Earlier he held management positions at MSD and Searle in the United States and Europe. Mr. Poussot holds a degree from the Ecole Supérieure de Commerce de Paris.
Daniel Ricquier, Ph.D.
Daniel Ricquier, Ph.D. is Professor at University Paris Descartes and a member of the French Academy of Sciences. He previously held faculty and research positions at University Pierre and Marie Curie, Centre National de Recherches Scientifiques and Hôpital Necker-Enfants Malades. He has conducted ground breaking and pioneering research on mitochondria bioenergetics, brown and white adipose tissues, energy balance and thermogenesis. He discovered uncoupling protein 1 (UCP1) and uncoupling protein 2 (UCP2) and went on to describe in details their roles in oxidative phosphorylation, thermogenesis, cardiovascular and metabolic diseases. He authored many manuscripts and reviews on uncoupling proteins, mitochondria, energy balance and obesity. As such, he is recognized as an international leader in these fields. Daniel Ricquier trained in physiology and biochemistry at Rouen University, Paris-Orsay University and Pierre and Marie University where he completed his Sc.D.
André Ulmann, M.D., Ph.D.
Dr. Ulmann is Chairman of HRA Pharma, a company that he created in 1996 and managed until 2009. Under his leadership, HRA Pharma developed into a pharmaceutical leader in contraception and orphan diseases. Previously, Andre Ulmann served as Medical Director and Head of Clinical Research for Roussel-Uclaf and HMR (later Sanofi-Aventis) with global responsibility in endocrinology, immunology, neurobiology, and bone diseases. Andre Ulmann holds an M.D. degree from the University of Paris VII and a Ph.D. from the University of Paris VI, France.
Huntington Willard, Ph.D.
Dr. Willard is Director, Geisinger National Precision Heath and Howard Hughes Medical Institute Professor. He was the President and Director of the Marine Biological Laboratory in Woods Hole, Massachusetts and Professor of Human Genetics at the University of Chicago. He previously held faculty positions at the University of Toronto, Stanford University, and Case Western Reserve University and most recently was the founding director of the Duke Institute for Genome Sciences & Policy and the Nanaline H. Duke Professor of Genome Sciences at Duke University. He is a respected leader in the fields of human genetics and genome biology and is the author or co-author of over 350 scientific publications. He is co-author of Genetics in Medicine and co-editor of Genomic and Personalized Medicine. Dr. Willard received his Ph.D. in human genetics from Yale University and is a member of both the National Academy of Sciences and the American Academy of Arts & Sciences.